Table 2.

Subgroup analyses of included studies

	N	Event, %	95% CI
FSGS
Remission
RTX < 1500 mg/m2	2	78.5	59.7–90.0
RTX ≥ 1500 mg/m2	3	48.4	4.0–99.5	Q = 0.235, p = 0.628
Prior to 2015	2	31.7	1.0–95.6
2015 and later	3	65.3	14.7–95.4	Q = 0.367, p = 0.545
Relapse
RTX < 1500 mg/m2	3	45.3	18.1–75.6
RTX ≥ 1500 mg/m2	1	57.1	23.0–85.6	Q = 0.220, p = 0.639
Prior to 2015	2	31.8	15.0–55.2
2015 and later	2	67.3	37.6–87.5	Q = 3.445, p = 0.063
MCD
Remission
RTX < 1500 mg/m2	6	86.5	72.0–94.1
RTX ≥ 1500 mg/m2	5	73.4	53.2–87.1	Q = 1.669; p = 0.196
Prior to 2015	6	81.6	70.2–89.3
2015 and later	5	79.7	51.8–93.5	Q = 0.027, p = 0.871
Relapse
RTX < 1500 mg/m2	6	31.3	20.7–44.4
RTX ≥ 1500 mg/m2	4	41.7	22.5–63.8	Q = 0.687, p = 0.407
Prior to 2015	6	37.3	23.4–53.8
2015 and later	4	32.2	15.6–55.1	Q = 0.145, p = 0.703